Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Regen BioPharma (RGBP) over the last 13 years, with Q3 2025 value amounting to $164672.0.

  • Regen BioPharma's Other Operating Expenses rose 8171.3% to $164672.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $392862.0, marking a year-over-year decrease of 398.96%. This contributed to the annual value of $488263.0 for FY2025, which is 1067.31% up from last year.
  • According to the latest figures from Q3 2025, Regen BioPharma's Other Operating Expenses is $164672.0, which was up 8171.3% from $69124.0 recorded in Q2 2025.
  • In the past 5 years, Regen BioPharma's Other Operating Expenses ranged from a high of $403680.0 in Q4 2022 and a low of $50711.0 during Q2 2021
  • Over the past 5 years, Regen BioPharma's median Other Operating Expenses value was $92011.0 (recorded in 2024), while the average stood at $115271.1.
  • Per our database at Business Quant, Regen BioPharma's Other Operating Expenses surged by 24091.43% in 2022 and then tumbled by 6980.28% in 2023.
  • Over the past 5 years, Regen BioPharma's Other Operating Expenses (Quarter) stood at $118411.0 in 2021, then surged by 240.91% to $403680.0 in 2022, then tumbled by 69.8% to $121900.0 in 2023, then decreased by 12.12% to $107126.0 in 2024, then soared by 53.72% to $164672.0 in 2025.
  • Its Other Operating Expenses was $164672.0 in Q3 2025, compared to $69124.0 in Q2 2025 and $159066.0 in Q1 2025.